Recombinant Human B-cell lymphoma/leukemia 10 (BCL10)

In Stock
Code CSB-EP002608HU
Size $224
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 90% as determined by SDS-PAGE.
Target Names
BCL10
Uniprot No.
Research Area
Apoptosis
Alternative Names
AI132454; B cell CLL/lymphoma 10 ; B cell lymphoma/leukemia10; B-cell CLL/lymphoma 10; B-cell leukemia/lymphoma 10; B-cell lymphoma/leukemia 10; Bcl 10; Bcl-10; Bcl10; BCL10_HUMAN; c E10; c-E10; C81403; CARD containing apoptotic signaling protein; CARD containing molecule enhancing NF kappa B; CARD containing molecule enhancing NF kB; CARD containing molecule enhancing NF-kB; CARD containing molecule enhancing NFkB ; CARD containing proapoptotic protein; CARD like apoptotic protein ; CARD-containing apoptotic signaling protein; CARD-containing molecule enhancing NF-kappa-B; CARD-containing proapoptotic protein; CARD-like apoptotic protein; CARMEN; Caspase recruiting domain containing protein ; caspase-recruiting domain-containing protein; cCARMEN; cE 10; cE10 ; CED 3/ICH 1 prodomain homologous E10 like regulator; CED-3/ICH-1 prodomain homologous E10-like regulator; CED3/ICH1 prodomain homologous E10 like regulator; Cellular E10; Cellular homolog of vCARMEN; Cellular-E10; CIPER; CLAP; hCLAP; Mammalian CARD containing adapter molecule E10; Mammalian CARD-containing adapter molecule E10; mE 10; mE10; R-RCD1
Species
Homo sapiens (Human)
Source
E.coli
Expression Region
1-233aa
Target Protein Sequence
MEPTAPSLTEEDLTEVKKDALENLRVYLCEKIIAERHFDHLRAKKILSREDTEEISCRTSSRKRAGKLLDYLQENPKGLDTLVESIRREKTQNFLIQKITDEVLKLRNIKLEHLKGLKCSSCEPFPDGATNNLSRSNSDESNFSEKLRASTVMYHPEGESSTTPFFSTNSSLNLPVLEVGRTENTIFSSTTLPRPGDPGAPPLPPDLQLEEEGTCANSSEMFLPLRSRTVSRQ
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
42.3kDa
Protein Length
Full Length
Tag Info
N-terminal 6xHis-SUMO-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

The gene coding for the Human BCL10 protein (1-233aa) is introduced into a plasmid vector, creating recombinant plasmid that is subsequently transformed into e.coli cells. e.coli cells capable of surviving in the presence of a specific antibiotic are selected and then cultured under conditions favorable for the expression of the gene of interest. A N-terminal 6xHis-SUMO tag is attached to the protein. Post-expression, the recombinant Human BCL10 protein is isolated and purified from the cell lysate using affinity purification. Denaturing SDS-PAGE is applied to resolve the resulting recombinant Human BCL10 protein, revealing a purity exceeding 90%.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation. Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex. This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity. Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK.
Gene References into Functions
  1. Results show that GSK3beta modulates serine phosphorylation of BCL10. PMID: 29358699
  2. BCL10 forms CARMA1-BCL10-MALT1-TRAF6 signalosome and BCL10 polymerizes in a unidirectional manner. PMID: 29382759
  3. The results suggest that the involvement of BCL10 in DNA damage-induced NF-kappaB is through the recruitment of TRAF6. PMID: 28717989
  4. results define molecular determinants that control the production of Lin(Ub)n-Bcl10, an important signaling intermediate in TCR and oncogenic CARD11 signaling. PMID: 27777308
  5. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation PMID: 27071417
  6. BCL10 promoted DNA double-strand breaks repair, enhancing cell survival after DNA damage. PMID: 26771713
  7. Data show that caspase recruitment domain-containing protein 11/B-cell CLL/lymphoma 10/mucosa-associated lymphoid tissue lymphoma translocation gene 1 signaling drives lymphoproliferation through NF-kappa B and c-Jun N-terminal kinase activation. PMID: 26668357
  8. BCL10 is not essential for actin polymerization after fibroblast FcgammaR stimulation. PMID: 26774590
  9. characterization of zebrafish (Danio rerio) Bcl10 PMID: 25849213
  10. we identified BCL10 as a bona fide target of BCR-induced linear ubiquitylation and demonstrated an important role of the linear ubiquitin ligase HOIP in BCR-induced phosphorylation PMID: 26038114
  11. The results of this study indicate that inherited BCL10 deficiency should be considered in patients with combined immunodeficiency with B cell, T cell, and fibroblast defects. PMID: 25365219
  12. B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway. PMID: 24681956
  13. BCL10 induces cleavage of MALT1 at R149 in 293T cells. PMID: 25105596
  14. Overexpression of CARMA-BCL10-MALT in T-ALL may contribute to the constitutive cleavage and inactivation of A20, which enhances NF-kappaB signaling and may be related to T-ALL pathogenesis. PMID: 25384343
  15. BCL10 delivers UBC13 to RNF8/RNF168 to regulate ubiquitination-mediated double-strand break signaling and repair. PMID: 24732096
  16. elevated in cholesteatoma PMID: 24702227
  17. A novel susceptibility locus on 1p22 was discovered, which implicates BCL10 as a new susceptibility gene for leprosy. PMID: 23784377
  18. Combining crystallography, nuclear magnetic resonance, and electron microscopy, we reveal the structure of the Bcl10 CARD filament and the mode of interaction between CARMA1 and Bcl10 PMID: 24074955
  19. BCL10 expression is a useful marker for acinar cell differentiation, particularly in the diagnosis of endoscopic ultrasound-guided fine-needle aspiration specimens of Acinar cell carcinomas of the pancreas PMID: 23530562
  20. Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance. PMID: 22708078
  21. BCL10 was commonly down-regulated in peripheral T cell lymphomas, suggest the T-cell receptor signaling cascade for future characterization. PMID: 22818167
  22. identify Bcl10 as an early coordinator of NF-kappaB-mediated immune response with endosomal trafficking and signaling to F-actin remodeling PMID: 23153494
  23. Results indicate that NF-kappaB binding to the BCL10 promoter can lead to prolonged activation of the carrageenan-induced inflammatory cascade by a transcriptional mechanism involving an NF-kappaB-BCL10 loop. PMID: 22579587
  24. A proapoptotic role for protein kinase C zeta in the binding and phosphorylating Bcl10 at the nuclear envelope. PMID: 22812606
  25. BCL10 plays an important role in controlling the growth of cervical cancer cells through NF-kappaB dependent cyclin D1 regulation. PMID: 22564715
  26. FOXO3a promotes cell survival via BCL10/NF-kappaB in serum starvation PMID: 22474286
  27. identify MIB2 as a novel component of the activated BCL10 signaling complex and a missing link in the BCL10-dependent NF-kappaB signaling pathway. PMID: 21896478
  28. findings indicate that BCL10 phosphorylations act upstream of phosphorylations of NIK, TAK1, and IkappaBalpha and differentially affect the canonical and noncanonical pathways of NF-kappaB activation PMID: 21700900
  29. Findings demonstrate that CaN functions as a critical signaling molecule during Th cell activation, regulating Bcl-10 phosphorylation and NF-kappaB activation. PMID: 21674474
  30. study shows CaMKII is recruited to the immunological synapse where it interacts with and phosphorylates Bcl10; propose a mechanism whereby Ca(2+) signals can be integrated at the immunological synapse through CaMKII-dependent phosphorylation of Bcl10 PMID: 21513986
  31. Data show that CARMA3 and Bcl10 contributed to several characteristics of EGFR-associated malignancy, including proliferation, survival, migration, and invasion. PMID: 21406399
  32. Lipopolysaccharide induces activation of both canonical and non-canonical pathways of NF-kappaB and the non-canonical pathway requires phosphorylations of BCL10 (serine 138) and NIK. PMID: 20466000
  33. A novel mutation of Bc1-10 gene in ocular adnexal MALT lymphoma was detected in Chinese patients. PMID: 18307945
  34. BCL10 nuclear expression is common in ocular adnexal mucosa-associated lymphoid tissue lymphomas. PMID: 19035248
  35. activation of NF-kappaB by CXCR4 occurs through Carma3/Bcl10/Malt1 (CBM) complex in OSCC. loss of components of CBM complex in HNSCC can inhibit SDF-1 alpha induced phosphorylation and degradation of IkappaBalpha. PMID: 20695076
  36. Interaction of calmodulin with Bcl10 modulates NF-kappaB activation. PMID: 20439115
  37. A specific single nucleotide polymorphism in the BCL10 gene may be responsible for the tumorigenesis of intracranial germinomas in Japanese individuals. PMID: 19690445
  38. Results suggest that the NFkappaB regulator BCL10 is an IL-2-independent STAT5 target gene. PMID: 19709433
  39. These findings indicate an upstream signaling role for BCL10, in addition to its effects on IKKgamma, the regulatory component of the IKK signalosome, and a requirement for BCL10 in both canonical and noncanonical pathways of NF-kappaB activation. PMID: 19897484
  40. vimplicated in apoptosis, and it has been suggested that mutated forms gain oncogenic activity. The occurrence of genomic BCL10 mutations in gastric MALT-type lymphomas was investigated. PMID: 11830492
  41. Mutations, relatively common in lymphomas, are extremely rare in malignant cartilaginous tumors. PMID: 11836626
  42. REVIEW: Genetic alterations involving BCL10 underlying the pathogenesis of MALT lymphoma PMID: 11960389
  43. There is a lack of BCL10 mRNA mutation in lymphold malignancies. PMID: 12017308
  44. association of mutations with aberrant BCL10 localization in the nucleus in nasal NK/T-cell lymphomas PMID: 14523480
  45. Bcl10 is post-translationally modified by Rip2 and has a role in T-cell signaling PMID: 14638696
  46. Nuclear expression of BCL10 is unlikely to correlate with the API2-MALT1 fusion gene in ocular adnexal MALT lymphoma. PMID: 14674990
  47. Together, these findings suggest that Bcl10 nuclear expression may modulate gene expression and Bcl10 is a potential transcriptional activator apart from its traditional roles that have been found. PMID: 15207693
  48. BinCard inhibits BCL10-mediated activation of NF-kappa B. PMID: 15637807
  49. The ability of Bcl10 expression to prevent B-cell antigen receptor-induced growth arrest and apoptosis of WEHI-231 cells was dependent on NF-kappaB activation. PMID: 15878976
  50. nucleocytoplasmic shuttling of MALT1 and BCL10 complex may indicate that these molecules are involved not only in the nuclear factor kappaB (NF-kappaB) pathway but also in other biologic functions in lymphocytes PMID: 16123224

Show More

Hide All

Involvement in disease
Immunodeficiency 37 (IMD37); Lymphoma, mucosa-associated lymphoid type (MALTOMA)
Subcellular Location
Cytoplasm, perinuclear region. Membrane raft.
Tissue Specificity
Ubiquitous.
Database Links

HGNC: 989

OMIM: 137245

KEGG: hsa:8915

STRING: 9606.ENSP00000271015

UniGene: Hs.193516

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*